Sponsor
  • ·
  • Chinese Association of
    Integrative Medicine;
    China Academy of Chinese
    Medicine Sciences
Editing
  • ·
  • Editorial Board of
    China Journal of
    Orthopaedics and Traumatology
Publishing
  • ·
  • Publishing House,
    China Journal of
    Orthopaedics and Traumatology
Overseas Distributor
  • ·
  • China International Book
    Trading Corporation
    P.O.Box 399,Beijing,China
    Code No.M587
Mail-order
  • ·
  • Publishing House,
    China Journal of
    Orthopaedics and Traumatology
    No.16A, Nanxiaojie, Dongzhimennei,
    Beijing 100700,China
    Tel:0086-10-84020925
    Fax:0086-10-84036581
    Http://www.zggszz.com
    E-mail:zggszz@sina.com
重组核因子κB活化因子受体蛋白预防小鼠骨质疏松的研究
摘要点击次数: 2412   全文下载次数: 1806   投稿时间:2012-08-13    
作者Author单位UnitE-Mail
张里程 ZHANG Li-cheng 中国人民解放军总医院骨科, 北京 100853 Department of Orthopaedics, General Hospital of Chinese PLA, Beijing 100853, China  
吕厚辰 LÜ Hou-chen 中国人民解放军总医院骨科, 北京 100853 Department of Orthopaedics, General Hospital of Chinese PLA, Beijing 100853, China  
熊琦 XIONG Qi 中国人民解放军总医院骨科, 北京 100853 Department of Orthopaedics, General Hospital of Chinese PLA, Beijing 100853, China  
张立海 ZHANG Li-hai 中国人民解放军总医院骨科, 北京 100853 Department of Orthopaedics, General Hospital of Chinese PLA, Beijing 100853, China  
唐佩福 TANG Pei-fu 中国人民解放军总医院骨科, 北京 100853 Department of Orthopaedics, General Hospital of Chinese PLA, Beijing 100853, China pftang301@126.com 
期刊信息:《中国骨伤》2013年26卷,第5期,第414-418页
DOI:10.3969/j.issn.1003-0034.2013.05.016
基金项目:国家自然科学基金(编号:81000796,30973068);军医进修学院博士研究生创新基金 (编号:11BCZ02)


目的: 探讨一种原核表达的重组核因子κB活化因子受体蛋白对破骨细胞活性及去卵巢小鼠骨质疏松预防作用, 并与目前临床应用最广泛的抗骨质疏松药物-阿伦磷酸钠进行疗效对比。

方法: 雌性KM小鼠24只, 3月龄, 卵巢切除造模后按体重随机分3组:重组核因子κB活化因子受体蛋白组(1.5 mg/kg,2次/周),阿伦磷酸钠治疗组(0.21 mg/kg,1次/周),对照组(PBS缓冲液, 0.2 ml,2次/周).给药12周后, 通过体重、血清钙、血清磷、血清碱性磷酸酶、骨组织TRAP染色破骨细胞计数及Micro-CT检查进行疗效评估。

结果: 给药12周后, 对照组骨密度(BMD) (92.600±14.319) mg/cc,骨小梁厚度(Tb.Th)(0.094±0.011) mm,骨小梁间距(Tb.Sp)(0.455±0.124) mm,骨体积分数(BVF)0.192±0.023,结构模型指数(SMI)1.388±0.328; 重组核因子κB活化因子受体蛋白组BMD(133.050±13.022) mg/cc, Tb.Th (0.098±0.009) mm,Tb.Sp (0.365±0.105) mm,BVF (0.291±0.025)%,SMI 0.661±0.384;阿伦磷酸钠治疗组BMD(128.013±16.040) mg/cc,Tb.Th (0.097±0.011) mm,Tb.Sp (0.376±0.104) mm,BVF 0.281±0.024,SMI 0.753±0.307.重组核因子κB活化因子受体蛋白能有效抑制去卵巢引起的骨质疏松, 具有与阿伦磷酸钠同等效果。与PBS对照组相比, 重组核因子κB活化因子受体蛋白治疗组股骨远端BMD增加明显, BVF增加, 骨小梁结构致密, Tb.Th明显变宽, Tb.Sp变窄, SMI降低, 股骨远端脱钙切片TRAP染色破骨细胞几乎完全被抑制。

结论: 在小鼠骨质疏松模型中, 重组核因子κB活化因子受体蛋白具有阿伦磷酸钠同等疗效, 能明显抑制破骨细胞的吸收活性, 并预防去卵巢引起的骨量丢失。
[关键词]:骨质疏松  破骨细胞  卵巢切除术  小鼠
 
Inhibitory effect of recombinant receptor activator of nuclear factor κB protein on bone loss in ovariectomized mice
Abstract:

Objective: To compare inhibitory effects of recombinant receptor activator of nuclear factor κB protein with bisphosphonate treatment (ALN) on osteoclasts activity and bone loss in ovariectomized mice.

Methods: Twenty-four female KM mice were ovariectomized bilaterally and treated with recombinant receptor activator of nuclear factor κB protein,alendronate,or PBS. Twelve weeks later,body weight,biochemical markers of bone metabolism,Micro CT scan and bone morphology were examined.

Results: After 12 weeks administration,the Micro CT scan and bone morphology values of each group were as follow. The control group:BMD (92.600±14.319) mg/cc,Tb.Th (0.094±0.011) mm,Tb.Sp(0.455±0.124) mm,BVF 0.192±0.023,SMI 1.388±0.328;the recombinant receptor activator of nuclear factor κB protein group:BMD(133.050±13.022) mg/cc,Tb.Th(0.098±0.009) mm,Tb.Sp(0.365±0.105) mm,BVF (0.291±0.025)%,SMI 0.661±0.384; the ALN group:BMD(128.013±16.040) mg/cc,Tb.Th(0.097±0.011) mm,Tb.Sp(0.376±0.104) mm,BVF 0.281±0.024,SMI 0.753±0.307. In the ovariectomized mice experiments,both recombinant receptor activator of nuclear factor κB protein and ALN significantly inhibited ovariectomy-induced bone loss. Compared to the control group (PBS),the recombinant receptor activator of nuclear factor κB protein group showed increased distal femur BMD and decreased trabecular spacing (Tb.Sp),whereas the control group had significantly decreased distal femur BMD,significantly decreased Tb.Th,and increased Tb.Sp. There was a significant difference in bone volume fraction among the groups. The TRAP-positive osteoclasts in distal femur bone slices were nearly complete inhibited for Recombinant receptor activator of nuclear factor κB protein group and alendronate group.

Conclusion: In vivo,recombinant receptor activator of nuclear factor κB protein effectively inhibits the activity of osteoclasts and the resulting bone loss,which has a similar effect as alendronate.
KEYWORDS:Osteoporosis  Osteoclasts  Ovariectomy  Mice
 
引用本文,请按以下格式著录参考文献:
中文格式:张里程,吕厚辰,熊琦,张立海,唐佩福.重组核因子κB活化因子受体蛋白预防小鼠骨质疏松的研究[J].中国骨伤,2013,26(5):414~418
英文格式:ZHANG Li-cheng,LÜ Hou-chen,XIONG Qi,ZHANG Li-hai,TANG Pei-fu.Inhibitory effect of recombinant receptor activator of nuclear factor κB protein on bone loss in ovariectomized mice[J].zhongguo gu shang / China J Orthop Trauma ,2013,26(5):414~418
查看全文  查看/发表评论  下载PDF阅读器
关闭




版权所有:《中国骨伤》杂志社京ICP备12048066号  版权声明
地址:北京市东直门内南小街甲16号,100700
电话:010-64089487 传真:010-64089792 Email:zggszz@sina.com